Category: Accesswire

52% OF VOTERS SAY ECONOMY IS BETTER TODAY THAN UNDER BIDEN, UP 5 PTS. FROM JANUARY

65% OF VOTERS AGREE WITH THE SUPREME COURT’S DECISION LIMITING EXECUTIVE POWER TO IMPOSE TARIFFS IN NON-EMERGENCIES

85% OF VOTERS SAY ONLY U.S. CITIZENS SHOULD BE ALLOWED TO VOTE WITH 71% SUPPORTING THE SAVE AMERICA ACT

THE MIDTERMS HORSERACE IS TIED, BUT REPUBLICANS HAVE A 4-PT. MESSAGING EDGE AMONG LIKELY VOTERS

76% OF AMERICANS SUPPORT FREE ENTERPRISE OVER SOCIALIST POLICIES, WITH STRONG CONSENSUS FOR PRIVATE HOMEOWNERSHIP, PROPERTY RIGHTS, AND PRIVATELY RUN GROCERY STORES

59% OF VOTERS NOW SUPPORT MADURO’S ARREST AND VENEZUELA INTERVENTION, A 5-PT. INCREASE, AND 62% SAY TRUMP ADMINISTRATION SHOULD PUSH VENEZUELA TOWARDS DEMOCRACY

NEW YORK, NY and CAMBRIDGE, MA / ACCESS Newswire / March 2, 2026 / Stagwell (NASDAQ: STGW) today released the results of the February Harvard CAPS / Harris poll, a monthly collaboration between the Center for American Political Studies at Harvard (CAPS) and the Harris Poll and HarrisX.

President Donald Trump’s approval rating is at 46%, showing slight improvements across nearly every policy area. His job approval is highest on fighting crime in America’s cities (51%), immigration (48%), and returning America to its values (48%); and lowest on responding to anti-ICE protests in Minneapolis (42%) and tariffs and trade policy (43%). This month’s poll also covered public opinion on the State of the Union, overall economy, midterms, recent Supreme Court ruling, voter ID requirements, economic ideology, and U.S. foreign policy in Latin America, the Middle East, and Ukraine. We will release a special follow-up report later this week on the conflict in Iran. Download the key results here.

“The Americans are single-mindedly focused on the economy, and this poll shows there is room for people to change their opinion as we’re seeing some improvement in the long-term trend,” said Mark Penn, Co-Director of the Harvard CAPS / Harris poll and Stagwell Chairman and CEO. “The administration has to keep working on explaining its economic policy to change the minds of voters ahead of the midterms.”

SLIGHT IMPROVEMENT IN PERCEPTIONS OF THE ECONOMY

• 51% of voters say the U.S. economy is strong today (+2 pts., Jan. 2026; +8 pts., Nov. 2025).

• 36% of voters say their personal financial situation is improving (+4 pts., Nov. 2025), particularly among Republican, male, likely midterm, 25-44 y.o., and urban voters.

• 52% of voters say the economy is better today than it was when Biden was president (+5 pts., Jan. 2026). 59% attribute today’s economy to Trump (Democrats: 75%; Republicans: 44%; Independents: 58%).

• 52% of voters say the economy is shrinking (-4). 62% think inflation is above 3 percent, including a majority across political parties (-4).

VOTERS CONTINUE TO SUPPORT MOST OF TRUMP’S POLICIES

• The majority of key Trump policies continue to see majority support. His most popular policies are lowering prescription drug prices (80% support), deporting illegal immigrants who have committed crimes (75%), eliminating fraud in government expenditures (71%), and capping credit card interest rates at 10% for one year (69%).

• Trump’s least popular policies include removing information about civil rights and climate change from public sites (32% support), Medicaid cost cuts (42%), and hiring additional ICE agents to conduct immigration raids (45%).

• Inflation and immigration continue to be the nation’s top two most important issues today, according to voters, with healthcare increasing in salience this month (+3).

• The Republican Party approval rating is at 48% (+4 pts., Jan. 2026), while the Democratic Party approval rating is at 45% (+1). Congressional approval is at 34% (+2).

FAVORABLE RESPONSE TO STATE OF THE UNION WITH NEW TRUMP POLICIES SEEING STRONG SUPPORT

• 47% of voters say they watched the State of the Union address, with 60% who watched at least some of the address having a favorable opinion of it.

• All 11 of Trump’s new policies announced in the address received majority support, with the most popular being a stock trading ban on Congressional members (72%), federal accounts for employees without retirement plans (70%), a ban preventing single-family home purchases from Wall Street firms (69%), and a most-favored-nation drug pricing deal (68%).

• 52% of voters say it was appropriate for some Democrats to boycott the address, but 57% say their booing and jeering was inappropriate.

• 33% of voters watched the Democratic rebuttal speech by Virginia governor Abigail Spanberger, with 61% who watched at least some of the speech having a favorable opinion of it.

REPUBLICANS GAIN EDGE POST-EXPOSURE TO PARTY MESSAGING IF CONGRESSIONAL ELECTIONS WERE HELD TODAY

• Voters are split 50-50 on which party they would vote for if the congressional election were held today (Republicans +4 pts., Jan. 2026).

• When given statements about party messaging, Republican messaging on responsible governance via curbed spending, closed borders, and reduced crime resonates most, with more than 2 in 5 voters, a plurality, saying the messages make them more likely to vote Republican.

• Anti-Trump messaging from Democrats is more effective than affordability messaging, with 61% of voters saying messages on stopping Trump and his tariffs are believable. However, the message only delivers a net +2 boost in likely vote choice toward Democrats.

• After exposure to each party’s messaging, 51% of voters say they are more likely to vote for a Republican for Congress than a Democrat. The Republican lead grows to 4 pts. among likely voters.

VOTERS AGREE WITH SUPREME COURT RULING AGAINST TRUMP’S TARIFFS

• 65% of voters agree with the Supreme Court’s ruling limiting Trump’s power to impose global tariffs without congressional approval, including a majority across political parties.

• 62% of voters say fentanyl/drug trafficking and large U.S. trade deficits are real issues and emergencies facing the country (Democrats: 43%; Republicans: 81%; Independents: 59%), but 42%, a plurality, say the president should not have authority to impose tariffs in non-emergency situations.

• 56% of voters oppose Trump’s new 15% global tariff after the Supreme Court ruling.

• 51% of voters oppose Trump’s tariffs imposed last year, with 54% saying the tariffs went too far.

MOST VOTERS BACK THE SAVE AMERICA ACT, BELIEVING ONLY U.S. CITIZENS SHOULD BE ALLOWED TO VOTE

• 58% of voters believe there is at least some voter fraud in U.S. elections, particularly among Republicans (77%) and Independents (58%), despite 60% saying the elections are generally secure.

• 85% of voters say only U.S. citizens should be allowed to vote, including a strong majority across political parties.

• 71% of voters support the SAVE America Act (Democrats: 50%; Republicans: 91%; Independents: 69%), with 54% prioritizing stopping voter fraud over access concerns for eligible citizens.

• The majority of voters support specific requirements of the Act, including proof of citizenship (75%), voter ID (81%), states removing non-citizens from voter rolls (80%), and states sharing redacted voting rolls with the Department of Homeland Security (61%).

• 73% of voters say we should have a national law requiring all ballots to be counted within 24 hours of Election Day.

• 68% of voters support early voting, including a majority across political parties.

AMERICANS ARE OVERWHLEMINGLY PRO-FREE ENTERPRISE

• 76% of voters say America should be run as a free enterprise country, including a strong majority across political parties, and 78% believe they have a better life under such a system.

• 59% say capitalism is a better economic system than socialism (Democrats: 46%; Republicans: 74%; Independents: 57%).

• 91% of voters support private homeownership, private property rights, and freedom of opinion. 84% believe grocery stores should be privately run.

• 65% of voters believe the people own their own houses, not the state, under socialism, including a majority across political parties.

• 52% of voters say teachers’ unions are heavily involved in politics, with most viewing them as in the political center (41%) or left-leaning (37%). 60% say they should not be involved in political issues (Democrats: 50%; Republicans: 63%; Independents: 66%).

MAJORITY SUPPORT FOR TRUMP’S GAZA DEAL

• 73% of voters support Trump’s deal to secure the safe return of Israeli hostages and end hostilities in Gaza (+6), including a majority across political parties and age groups.

• 71% of voters continue to support Israel over Hamas in the conflict.

MORE VOTERS SUPPORT MADURO’S ARREST VERSUS LAST MONTH, WANT MORE AGGRESSIVE U.S. STANCE AGAINST DICTATORS AND DRUG CARTELS

• 59% of voters support the arrest of Nicolás Maduro (+5), with 58% saying his removal was in the national interest of the U.S. (+7; Democrats: 41%; Republicans: 79%; Independents: 52%).

• 54% of voters say the U.S. should try to fix the Venezuelan oil industry (-3), though 51% say the U.S. is not entitled to proceeds.

• 62% of voters believe pushing Venezuela towards a democratic transition should be a key priority for the Trump administration, including a majority across political parties.

• 67% of voters say the U.S. should take a more aggressive stand in our hemisphere against leaders propped up by drug cartels, and 62% support a U.S. maximum pressure campaign on the government of Mexico to fight drug cartels.

• 66% of voters think the U.S. should take a more aggressive stance against dictators propped up by Russia and China (+5).

MAJORITY OF VOTERS WANT THE U.S. TO CONTINUE SUPPORTING UKRAINE

• 66% of voters say Trump should continue to provide weapons to Ukraine and impose further economic sanctions on Russia, including a majority across political parties.

• 63% of voters say Ukraine should receive direct security guarantees from the U.S. if it makes concessions to end the war.

• 51% of voters support Trump’s handling of the Ukraine-Russia conflict so far.

The February Harvard CAPS / Harris poll survey was conducted online within the United States on February 25-26, 2026, among 1,999 registered voters by The Harris Poll and HarrisX. Follow the Harvard CAPS / Harris poll podcast at https://www.markpennpolls.com/ or on iHeart Radio, Apple Podcasts, Spotify, and other podcast platforms.

About The Harris Poll & HarrisX

The Harris Poll is a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. It works with clients in three primary areas: building twenty-first-century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. One of the longest-running surveys in the U.S., The Harris Poll has tracked public opinion, motivations, and social sentiment since 1963, and is now part of Stagwell, the challenger holding company built to transform marketing.

HarrisX is a technology-driven market research and data analytics company that conducts multi-method research in the U.S. and over 40 countries around the world on behalf of Fortune 100 companies, public policy institutions, global leaders, NGOs and philanthropic organizations. HarrisX was the most accurate pollster of the 2020 U.S. presidential election.

About the Harvard Center for American Political Studies
The Center for American Political Studies (CAPS) is committed to and fosters the interdisciplinary study of U.S. politics. Governed by a group of political scientists, sociologists, historians, and economists within the Faculty of Arts and Sciences at Harvard University, CAPS drives discussion, research, public outreach, and pedagogy about all aspects of U.S. politics. CAPS encourages cutting-edge research using a variety of methodologies, including historical analysis, social surveys, and formal mathematical modeling, and it often cooperates with other Harvard centers to support research training and encourage cross-national research about the United States in comparative and global contexts. More information at https://caps.gov.harvard.edu/.

Contact:
Carrie Hsu
pr@stagwellglobal.com

SOURCE: Stagwell

View the original press release on ACCESS Newswire

BOCA RATON, FL / ACCESS Newswire / February 27, 2026 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) today announced that more than four million Americans tuned in across the Company’s channels for the network’s comprehensive live coverage of President Donald Trump’s State of the Union address Tuesday night.

The coverage marks a major ratings and digital milestone for the Company.

Newsmax’s coverage began at 6:00pm ET with “Carl Higbie FRONTLINE” followed by “Rob Schmitt Tonight.”

Beginning at 8:00pm ET, the Newsmax network delivered wall-to-wall special coverage anchored live from Washington, D.C., by Greta Van Susteren and Rob Finnerty, with analysis from Mark Meadows, former White House chief of staff, and commentator Mercedes Schlapp.

The special broadcast continued through midnight, providing viewers with in-depth analysis, real-time reactions and exclusive interviews.

The Newsmax channel alone drew 2.8 million total viewers Tuesday night, according to Nielsen, while an additional 1.3 million streaming viewers watched coverage on Newsmax2, underscoring the growing reach of the Company’s digital platforms.

The Newsmax audience was so large on cable that its total audience exceeded the combined viewership of Fox Business, CNBC and NewsNation combined by 23%.

Throughout the evening, Newsmax’s editorial team provided regular updates to Newsmax.com and engaged the network’s more than 23 million social media followers with breaking developments, video highlights and expert commentary.

“The president gave an epic speech, and America tuned in, with a big chunk of his audience tuning into Newsmax,” said Newsmax CEO Chris Ruddy. “It was a big night for the president and for us.”

In addition to airing the president’s address live, Newsmax offered continual reporting and instant analysis from top newsmakers and commentators.

High-profile guests appearing on the network included Speaker of the House Mike Johnson, R-La., Majority Leader Steve Scalise, R-La., Health Secretary Robert F. Kennedy Jr. and HUD Secretary Scott Turner.

Other major figures included Sens. Rick Scott, R-Fla., Markwayne Mullin, R-Okla., Ron Johnson, R-Wis., John Cornyn, R-Texas, Ted Cruz, R-Texas, John Barrasso, R-Wyo. and Chris Coons, D-Del.

Additional contributors included Trish Regan, Trump presidential envoy Richard Grenell, presidential pollsters John McLaughlin and Dick Morris and House chairmen Rep. James Comer, R-Ky., and Rep. Jim Jordan, R-Ohio.

Other members of Congress appearing included Rep. Anna Paulina Luna, R-Fla., Rep. Dan Crenshaw, R-Texas, Rep. Byron Donalds, R-Fla., Rep. Brandon Gill, R-Texas and Rep. Chip Roy, R-Texas.

Newsmax2 also featured live coverage with anchors Ed Henry and Bianca de la Garza, providing viewers with additional perspectives and extended post-speech analysis across streaming platforms.

“Our network coverage was first-rate and was not only on par with major networks but delivered the kind of comprehensive reporting viewers don’t see much anymore,” said Gary Kanofsky, Newsmax’s senior vice president of news.

“From our anchors in Washington to our contributors and production teams across the country, this was a total newsroom effort,” he said.

The strong performance reflects Newsmax’s continued growth as a trusted destination for millions of Americans seeking live news events, in-depth analysis and diverse perspectives.

With expanded distribution across cable, satellite, OTT and streaming platforms, Newsmax continues to solidify its position as one of the nation’s leading news networks.

Millions of Americans are now watching Newsmax anytime, anywhere by downloading our free app on smartphones and TVs.

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 50 million Americans regularly through Newsmax TV, the N2 Channel, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches over 22 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Inc.

Investor Contacts
Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire

SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial results for the three and twelve months ended December 31, 2025.

Corporate Highlights

• Announced Positive Results from PRIME Clinical Study in late-stage chronic kidney disease patients

• Announced agreement with FDA on a single adaptive Phase 2/3 study for approval of Gemini for treatment of acute kidney injury

• Received net proceeds of $6.7 million from warrant inducement in January 2026

• Clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the International Conference on Advances in Critical Care Nephrology in San Diego (March 29 – April 1, 2026)

“2025 was a positive year for Revelation with significant advancement of the Gemini program,” said James Rolke, Chief Executive Officer of Revelation. “We look forward to building on this momentum in 2026 to expeditiously bring Gemini to patients in need and adding to shareholder value.”

Results of Operations

As of December 31, 2025, Revelation had $10.7 million in cash and cash equivalents, compared to $6.5 million as of December 31, 2024. The increase in cash and cash equivalents was primarily due to net cash proceeds from the May 2025 public offering and the September 2025 warrant inducement, offset by cash used for operating activities. Based on current operating plans and projections, Revelation believes its current cash and cash equivalents are sufficient to fund operations into the first quarter of 2027.

Net cash used for operating activities for the twelve months ended December 31, 2025 was $8.3 million compared to net cash used for operating activities of $18.3 million for the same period in 2024. Net loss for the three months ended December 31, 2025 was $2.5 million, or $(1.65) basic and diluted net loss per share, compared to a net loss of $1.7 million, or $(59.76) basic and diluted net loss per share for the same period in 2024. Net loss for the year ended December 31, 2025 was $8.9 million, or $(23.95) basic and diluted net loss per share compared to net loss of $15.0 million, or $(1,052.16) basic and diluted net loss per share for the year ended December 31, 2024.

About Gemini

Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD^®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response and has been demonstrated to have the potential to treat acute and chronic diseases associated with dysregulated inflammation. Gemini is currently being evaluated as a potential treatment for acute kidney injury (GEM-AKI); Gemini is also being developed as a treatment for chronic kidney disease (GEM-CKD), as a treatment to reduce hyperinflammation and infection associated with severe burn (GEM-PBI), and as a treatment to prevent post-surgical infection (GEM-PSI). The potential of Gemini to correct dysregulated inflammation has been demonstrated in multiple preclinical models of AKI, CKD, and infection, as well as in two phase 1 clinical studies. See additional detail here.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.

For more information, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

REVELATION BIOSCIENCES, INC.
Consolidated Statements of Operations

		Three Months Ended December 31,								Year Ended December 31,
		2025				2024				2025				2024
Operating expenses:
Research and development		$	964,189			$	605,504			$	4,063,857			$	3,548,996
General and administrative			1,607,398				1,148,384				5,006,957				4,426,113
Total operating expenses			2,571,587				1,753,888				9,070,814				7,975,109
Loss from operations			(2,571,587	)			(1,753,888	)			(9,070,814	)			(7,975,109	)
Other income (expense):
Change in fair value of warrant liability			87				2,557				2,158				81,441
Other income (expense), net			60,493				25,612				155,007				(7,144,868	)
Total other income (expense), net			60,580				28,169				157,165				(7,063,427	)
Net loss		$	(2,511,007	)		$	(1,725,719	)		$	(8,913,649	)		$	(15,038,536	)
Deemed dividends			–				–				(5,951,528	)			–
Net loss attributable to common stockholders			(2,511,007	)			(1,725,719	)			(14,865,177	)			(15,038,536	)
Net loss per share, basic and diluted		$	(1.65	)		$	(59.76	)		$	(23.95	)		$	(1,052.16	)
Weighted-average shares used to compute net loss per share, basic and diluted			1,524,011				28,876				620,785				14,293

REVELATION BIOSCIENCES, INC.
Consolidated Balance Sheets

		December 31, 2025				December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents		$	10,700,331			$	6,499,018
Prepaid expenses and other current assets			111,297				66,699
Total current assets			10,811,628				6,565,717
Property and equipment, net			18,067				56,332
Operating lease right-of-use asset			722,288				–
Other assets			30,941				–
Total assets		$	11,582,924			$	6,622,049
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable		$	577,501			$	783,621
Accrued expenses			1,397,644				1,130,046
Operating lease liability			23,013				–
Total current liabilities			1,998,158				1,913,667
Operating lease liability, net of current portion			723,771				–
Total liabilities			2,721,929				1,913,667
Commitments and Contingencies (Note 4)
Stockholders’ equity:
Common Stock, $0.001 par value; 500,000,000 shares authorized at December 31, 2025 and December 31, 2024 and 1,583,969 and 43,526 issued and outstanding at December 31, 2025 and December 31, 2024, respectively			1,584				44
Additional paid-in-capital			58,278,698				45,213,976
Accumulated deficit			(49,419,287	)			(40,505,638	)
Total stockholders’ equity			8,860,995				4,708,382
Total liabilities and stockholders’ equity		$	11,582,924			$	6,622,049

Company Contacts

Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

Sustained acoustic medicine (sam^®) helps players recover more quickly from workouts and injuries, such as the UCL tears, hamstring pulls, and oblique strains that are becoming more common in baseball.

TRUMBULL, CONNECTICUT / ACCESS Newswire / February 12, 2026 / As pitchers and catchers report next week to baseball’s spring training camps, ZetrOZ Systems will also be there, meeting with teams to present its sustained acoustic medicine (sam^®) technology. The company’s sam^® wearable ultrasound device is proven effective in helping athletes recover from workouts, avoid health issues and recover more quickly from common soft-tissue injuries.

ZetrOZ Systems has previously worked with the Professional Baseball Athletic Trainers Society to educate teams about how the device can assist in treating the most common baseball injuries: rotator cuff tears, UCL injuries, labral tears, hamstring and ankle sprains and tendonitis.

Those injuries are a growing problem in Major League Baseball. A 2024 MLB study found that major and minor league UCL surgeries have “increased substantially” since 2021. The report highlighted 41 UCL surgeries for major league players and 240 surgeries for minor league players in 2024.

Baseball injuries also occur more frequently during training camp and early in the season. The Orthopaedic Journal of Sports Medicine’s 2019 study found that about 40% of hamstring injuries in baseball occur in April and May. The Journal of Shoulder and Elbow Surgery’s 2021 report established that UCL injuries in baseball also peaked in the spring.

“Spring training is the time when baseball players prepare for the long road of the regular season, and it’s also when they may be most vulnerable to injury,” said Dr. George K. Lewis, founder and CEO of ZetrOZ Systems and the inventor of sustained acoustic medicine. “Our sam^® wearable ultrasound technology provides athletes with a clinically proven way to accelerate recovery and optimize performance. We’re hopeful that by meeting with teams this spring, we can help them keep their players healthy all the way to the World Series.”

The sam^® long-duration ultrasound device works by generating warmth deep into soft tissue, increasing blood flow and delivery of oxygenated hemoglobin at the site. That removes cytokine enzymes and cellular waste, which reduces pain and inflammation, improves function and range of motion, and shortens recovery time after workouts or injuries.

The effectiveness of sustained acoustic medicine and the sam^® device has been documented in more than 20 Level 1-5 clinical studies and more than 40 peer-reviewed journal articles. The sam^® device is also the only wearable ultrasound unit with FDA clearance for daily home use, which allows it to fit seamlessly into an athlete’s routine. Players can use the portable device while traveling or relaxing, making therapy and rehabilitation more manageable.

The sam^® device from ZetrOZ Systems helps both professional athletes and everyday people return to sports and daily activities without invasive treatments or potentially addictive pain medication. For more information about ZetrOZ Systems and the sam^® wearable ultrasound device, visit www.zetroz.com or www.samrecover.com.

About ZetrOZ Systems

ZetrOZ Systems is leading the way in healing innovations in sports medicine, developing wearable bioelectronic devices to deliver sustained acoustic medicine (sam^®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of 46 patents and is the exclusive manufacturer and developer of the sam^® product line, designed to treat acute and chronic musculoskeletal conditions.

Media Contact

Catherine Hoblin
choblin@zetroz.com

SOURCE: ZetrOZ Systems

View the original press release on ACCESS Newswire

Dr. Raza Bokhari, Exec Chairman & CEO, Interviewed by Bloomberg Open Interest Anchor Matt Miller

PHILADELPHIA, PA / ACCESS Newswire / February 12, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) (“Medicus” or the “Company”), a precision guided biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, CEO Dr Raza Bokhari joined Matt Miller from Bloomberg World for a live interview on February 10, 2026. https://youtu.be/2-naOb7uJRc?si=eumsbejKNkAdQ62G

In this live interview on Bloomberg World, Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, discusses the company’s strategy, the challenges facing biotech stocks, and how artificial intelligence is shaping its drug development efforts.

Central to the discussion is the role of AI in accelerating drug development. Dr. Bokhari outlines Medicus Pharma’s AI-driven approach, positioning the company’s leadership as both. investors and operators that have committed nearly $14 million of personal capital at $4 per share toward advancing its pipeline. He expresses confidence in his beliefs that continued AI-enabled progress, regulatory optionality, and upcoming catalysts, including Phase 2 clinical data readouts for Skinject in the first half of 2026, should materially change investor perception and unlock value, in the same manner it did in the first half of 2025, following the of a positively trending interim data analysis.

The conversation underscores both the short-term volatility in biotech markets and the company’s long-term belief in the potential of AI to transform innovative therapy development.

Click here to watch the full interview.

For further information contact:

Carolyn Bonner, President and Chief Financial Officer
(610) 636-0184
cbonner@medicuspharma.com

Anna Baran-Djokovic, SVP Investor Relations
(305) 615-9162
adjokovic@medicuspharma.com

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq:MDCX) is a precision-guided biotech/life sciences company focused on accelerating the clinical development programs of novel and potentially disruptive therapeutics assets. The Company is actively engaged in multiple countries across three continents.

SkinJect Inc., a wholly owned subsidiary of Medicus Pharma Ltd., is a development-stage life sciences company focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver a chemotherapeutic agent to eradicate tumor cells. The Company completed a Phase 1 study (SKNJCT-001) in March of 2021, which met its primary objective of demonstrating safety and tolerability; the study also describes the efficacy of the investigational product doxorubicin-containing microneedle arrays (D-MNA), with six participants experiencing complete response on histological examination of the resected lesion. The Company is currently conducting a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-003) in the United States and Europe. The Company has also commenced a randomized, controlled, double-blind, multicenter clinical study (SKNJCT-004) in the United Arab Emirates.

In August 2025, the Company announced its entry into a non-binding memorandum of understanding (MoU) with Helix Nanotechnologies, Inc. (HelixNano), a Boston-based biotech company focused on developing a proprietary advanced mRNA platform, in respect of their shared mutual interest in the development or commercial arrangement contemplated by the MoU. The MoU is non-binding and shall not be construed to obligate either party to proceed with a joint venture or any further development or commercial arrangement, unless and until definitive agreements are executed.

In August 2025, the Company completed the acquisition of Antev, a UK-based late clinical stage biotech company, developing Teverelix, a next-generation gonadotrophin-releasing hormone (GnRH) antagonist, as a first-in-market product for cardiovascular high-risk advanced prostate cancer patients and patients with first acute urinary retention relapse (AURr) episodes due to enlarged prostate.

Unlike GnRH agonists, which can cause an initial surge in testosterone levels, Teverelix directly suppresses sex hormone production without this surge, potentially reducing cardiovascular risks. This mechanism is particularly beneficial for patients with existing cardiovascular conditions. Teverelix is formulated as a microcrystalline suspension, allowing for sustained release and a six-week dosing interval, which may improve patient compliance and outcomes.

In September 2020, Antev completed a Phase 1 clinical trial in which Teverelix was shown to be well tolerated with no dose-limiting toxicities and demonstrated rapid testosterone suppression. The study included 48 healthy male volunteers. In February 2023, Antev also completed a Phase 2a study in 50 patients with advanced prostate cancer (APC), where Teverelix achieved the primary endpoint of greater than 90% probability of castration levels of testosterone suppression (97.5%) but the secondary endpoint of maintaining this rate above 90% was not met, with the probability dropping to 82.5% by Day 42.

In January 2023, the U.S. Food and Drug Administration (FDA) reviewed the Phase 1 and Phase 2a data and provided written guidance on Antev’s proposed Phase 3 trial design for Teverelix. This milestone supports the Company’s clinical plans to develop Teverelix as a treatment for advanced prostate cancer patients with increased cardiovascular risk.

In December 2023, the FDA approved the Phase 2b study design in advanced prostate cancer covering 40 patients.

In November 2024, the FDA approved the Phase 2b study design in AURr covering 390 patients.

In October 2025, the Company announced a strategic collaboration with the Gorlin Syndrome Alliance (GSA) to advance compassionate access to SkinJect for patients suffering from Gorlin Syndrome, also known as nevoid basal cell carcinoma syndrome.

Under the collaboration, Medicus and the GSA will jointly pursue the Expanded Access IND Program with the FDA to allow patients with multiple, recurrent, or inoperable basal cell carcinomas (BCCs) to access SkinJect under physician-supervised treatment protocols. The initiative aims to establish a framework for expanded access while collecting valuable real-world safety and tolerability data to inform future regulatory filings. It will also more tightly integrate patient community-led insights and data into the design, monitoring, and long-term development of SkinJect in this rare disease population.

In November 2025, the Company received full regulatory and ethical approvals in the United Kingdom to expand its ongoing Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The approvals were issued by the Medicines and Healthcare products Regulatory Agency (MHRA), the Health Research Authority (HRA) and the Wales Research Ethics Committee (WREC). The MHRA approval followed a comprehensive scientific review of the Investigational Medicinal Product Dossier (IMPD) and protocol. The WREC issued a favorable ethical opinion, and the HRA granted study-wide governance approval, confirming compliance with UK Good Clinical Practice and National Health Service capacity and capability standards.

In December 2025, the Company announced that it has successfully completed enrolment of 90 patients in the United States for Phase 2 clinical study (SKNJCT-003) evaluating D-MNA to non-invasively treat BCC of the skin. The Company expects to release topline results for SKNJCT-003 in the first quarter of 2026 and secure an end-of-Phase 2 meeting with the FDA in the first half of 2026.

In December 2025, Medicus announced a non-binding letter of intent with Reliant AI Inc., a decision-intelligence company specializing in generative AI for the life sciences industry, to collaborate on the development of an AI-driven clinical data analytics platform. Subject to execution of definitive agreements, the platform is expected to support capital-efficient clinical development through data-driven dynamic clinical-site selection, patient stratification and enrollment forecasting. The initial phase of the collaboration is expected to support an upcoming Teverelix clinical study planned for 2026, with potential expansion into later-stage development programs in collaboration with a strategic partner.

In February 2026, Medicus announced that it has received “study may proceed” clearance from the U.S. Food and Drug Administration (FDA) to initiate its Phase 2b dose-optimization study of Teverelix®, an investigational next generation long-acting GnRH antagonist, in men with advanced prostate cancer (APC).

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes “forward-looking information” under applicable securities laws. “Forward-looking information” is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes, without limitation, statements regarding the Company’s leadership and prospects, the collaboration with GSA including the potential benefits thereof for GSA, those suffering with Gorlin Syndrome and Medicus (including as it relates to the development of SkinJect^™), ability to be approved for the Expanded Access IND Program to enable those suffering with Gorlin Syndrome to access SkinJect^™ under physician-supervised treatment protocols, the development of Teverelix and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of Teverelix for AURr, high CV risk prostate cancer, women’s health indications like endometriosis, and the potential market opportunities related thereto, the MOU, including the potential signing of definitive agreements between Medicus and HelixNano and the development of thermostable infectious diseases vaccines by combining HelixNano’s proprietary mRNA vaccine platform with Medicus’s proprietary microneedle array (MNA) delivery platform, the Company’s aim to fast-track the clinical development program and convert the SKNJCT-003 exploratory clinical trial into a pivotal clinical trial, and approval from the FDA and the timing thereof, including with respect to the Company’s submission for approval in the FDA Commissioner’s National Priority Voucher program, plans and expectations concerning, and future outcomes relating to, the development, advancement and commercialization of SkinJect through SKNJCT-003 and SKNJCT-004, and the potential market opportunities related thereto, the Company’s expectation to release topline results for SKNJCT-003 in the first quarter of 2026 and to secure an EOP2 meeting with the FDA in the first half of 2026, entry into definitive documents with Reliant and the expected terms thereof, engaging in proposed Medicus-sponsored studies currently contemplated in the Reliant non-binding letter of intent and the expected benefits thereof, the expansion of SKNJCT-003 into the United Kingdom and the potential benefits therefrom, the advancement of the SKNJCT-004 study and the potential results of and benefits of such study. Forward-looking statements are often but not always, identified by the use of such terms as “may”, “on track”, “aim”, “might”, “will”, “will likely result”, “could,” “designed,” “would”, “should”, “estimate”, “plan”, “project”, “forecast”, “intend”, “expect”, “anticipate”, “believe”, “seek”, “continue”, “target”, “potential” or the negative and/or inverse of such terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including those risk factors described in the Company’s annual report on form 10-K for the year ended December 31, 2024 (the “Annual Report”), and in the Company’s other public filings on EDGAR and SEDAR+, which may impact, among other things, the trading price and liquidity of the Company’s common shares. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

SOURCE: Medicus Pharma Ltd

View the original press release on ACCESS Newswire

PHILADELPHIA, PA / ACCESS Newswire / February 11, 2026 / Datavault AI Inc. (NASDAQ:DVLT) (“Datavault AI” or the “Company”), a leader in data monetization, credentialing, digital engagement and real-world asset (RWA) tokenization technologies, announced that on Tuesday evening, Chief Executive Officer Nate Bradley hosted a private, invitation-only dinner at Mar-a-Lago for a select group of institutional investors, high-net-worth individuals, and senior government officials.

The private dinner followed successful, similar engagements earlier in the day at Mar-a-Lago, where Bradley met with a separate group of high-net-worth strategic investors. The strong reception from those discussions generated interest in a second, Datavault-hosted gathering, culminating in the private evening dinner.

Discussions during the engagements centered on Datavault AI’s execution roadmap, platform capabilities, and long-term positioning across data infrastructure, digital engagement, and monetization markets. The meetings reflected growing interest in the Company’s approach to verified data, tokenization frameworks, and scalable engagement technologies that bridge physical and digital environments.

The Mar-a-Lago engagements followed a period of elevated visibility and operational execution for Datavault AI. Earlier this month, the Company highlighted its high-impact activations during Super Bowl LX weekend, where its proprietary technologies were deployed in live environments to demonstrate authenticated audience engagement, immersive digital experiences, and real-world tokenization use cases. Those activations served as a real-world validation of the Company’s platforms and their ability to operate at scale.

In addition, Datavault AI recently issued a letter to stockholders outlining its 2025 accomplishments and outlook for 2026. In that update, the Company reported signing $49 million in tokenization and technology licensing agreements during the fourth quarter of 2025, contributing to record-setting revenue performance in fiscal 2025, with additional revenue impact extending into fiscal 2026. Datavault AI also reiterated expectations for at least $30 million in revenue for fiscal 2025, representing year-over-year growth of more than 1,000% compared to fiscal 2024. The Company expects to publish its fourth-quarter results on February 15, 2026.

“The level of engagement we experienced throughout the day, and the interest that carried into the evening, reflects a growing understanding of what Datavault AI has built and where we are headed,” said Nate Bradley, Chief Executive Officer of Datavault AI. “We are focused on execution and on delivering platforms that enable verifiable data, scalable engagement, and monetization in real-world environments. We appreciate the opportunity to engage directly with strategic investors and senior leaders as we continue advancing that mission.”

Datavault AI remains focused on expanding commercial deployments of its technologies, strengthening strategic partnerships, and advancing infrastructure that supports secure data processing, digital engagement, and real-world asset tokenization across multiple sectors.

About Datavault AI
Datavault AI™ (NASDAQ:DVLT) is leading the way in AI driven data experiences, valuation and monetization of assets in the Web 3.0 environment. The Company’s cloud-based platform provides comprehensive solutions with a collaborative focus in its Acoustic Science and Data Science Divisions. Datavault AI’s Acoustic Science Division features WiSA®, ADIO® and Sumerian ® patented technologies and industry-first foundational spatial and multichannel wireless HD sound transmission technologies with IP covering audio timing, synchronization and multi-channel interference cancellation. The Data Science Division leverages the power of Web 3.0 and high-performance computing to provide solutions for experiential data perception, valuation and secure monetization. Datavault AI’s cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The Information Data Exchange ® (IDE) enables Digital Twins, licensing of name, image and likeness (NIL) by securely attaching physical real-world objects to immutable metadata objects, fostering responsible AI with integrity. Datavault AI’s technology suite is completely customizable and offers AI and Machine Learning (ML) automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. The Company is headquartered in Philadelphia, PA. Learn more about Datavault AI at www.dvlt.ai.

Forward-Looking Statements
This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other securities laws) about Datavault AI Inc. (“Datavault AI,” the “Company,” “us,” “our,” or “we”) and our industry that involve risks and uncertainties. In some cases, you can identify forward-looking statements because they contain words, such as “may,” “might,” “will,” “shall,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “goal,” “objective,” “seeks,” “likely” or “continue” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. The absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements, including, but not limited to, statements regarding future events, the timing, scope and expected benefits of Datavault AI’s audience engagement activities and outreach, and the anticipated benefits of Datavault AI’s commercial partnerships and/or collaborations, including, without limitation, with Sports Illustrated, are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Readers are cautioned not to place undue reliance on these and other forward-looking statements contained herein.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various risks and uncertainties including, but not limited to, the following: risks related to the ability of Datavault AI to successfully implement its commercial partnerships, collaborations and/or strategies; changes in market demand for Datavault AI’s services and products; changes in economic, market, or regulatory conditions; risks relating to evolving regulatory frameworks applicable to tokenized assets; risks associated with technological development and integration; and other risks and uncertainties as more fully described in Datavault AI’s filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and other filings that Datavault AI makes from time to time with the SEC, which are available on the SEC’s website at www.sec.gov, and could cause actual results to vary from expectations.

The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. Datavault AI undertakes no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. Datavault AI may not actually achieve the plans, intentions or expectations disclosed in its forward-looking statements, and you should not place undue reliance on such forward-looking statements. Datavault AI’s forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments it may make.

Trademarks, Trade Names, Service Marks and Copyrights
We own or have rights to use various trademarks, tradenames, service marks and copyrights, which are protected under applicable intellectual property laws. This press release also contains trademarks, tradenames, service marks and copyrights of other companies, which are, to our knowledge, the property of their respective owners. Solely for convenience, certain trademarks, tradenames, service marks and copyrights referred to in this press release may appear without the © , ® , and symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, tradenames, service marks and copyrights. We do not intend our use or display of other parties’ trademarks, tradenames, service marks or copyrights to imply, and such use or display should not be construed to imply a relationship with, or endorsement or sponsorship of us by, these other parties.

Media Contact:
ir@dvlt.ai

SOURCE: Datavault AI Inc

View the original press release on ACCESS Newswire

Sustained acoustic medicine (sam^®) helps players recover more quickly from workouts and injuries, such as the UCL tears, hamstring pulls, and oblique strains that are becoming more common in baseball.

TRUMBULL, CONNECTICUT / ACCESS Newswire / February 12, 2026 / As pitchers and catchers report next week to baseball’s spring training camps, ZetrOZ Systems will also be there, meeting with teams to present its sustained acoustic medicine (sam^®) technology. The company’s sam^® wearable ultrasound device is proven effective in helping athletes recover from workouts, avoid health issues and recover more quickly from common soft-tissue injuries.

ZetrOZ Systems has previously worked with the Professional Baseball Athletic Trainers Society to educate teams about how the device can assist in treating the most common baseball injuries: rotator cuff tears, UCL injuries, labral tears, hamstring and ankle sprains and tendonitis.

Those injuries are a growing problem in Major League Baseball. A 2024 MLB study found that major and minor league UCL surgeries have “increased substantially” since 2021. The report highlighted 41 UCL surgeries for major league players and 240 surgeries for minor league players in 2024.

Baseball injuries also occur more frequently during training camp and early in the season. The Orthopaedic Journal of Sports Medicine’s 2019 study found that about 40% of hamstring injuries in baseball occur in April and May. The Journal of Shoulder and Elbow Surgery’s 2021 report established that UCL injuries in baseball also peaked in the spring.

“Spring training is the time when baseball players prepare for the long road of the regular season, and it’s also when they may be most vulnerable to injury,” said Dr. George K. Lewis, founder and CEO of ZetrOZ Systems and the inventor of sustained acoustic medicine. “Our sam^® wearable ultrasound technology provides athletes with a clinically proven way to accelerate recovery and optimize performance. We’re hopeful that by meeting with teams this spring, we can help them keep their players healthy all the way to the World Series.”

The sam^® long-duration ultrasound device works by generating warmth deep into soft tissue, increasing blood flow and delivery of oxygenated hemoglobin at the site. That removes cytokine enzymes and cellular waste, which reduces pain and inflammation, improves function and range of motion, and shortens recovery time after workouts or injuries.

The effectiveness of sustained acoustic medicine and the sam^® device has been documented in more than 20 Level 1-5 clinical studies and more than 40 peer-reviewed journal articles. The sam^® device is also the only wearable ultrasound unit with FDA clearance for daily home use, which allows it to fit seamlessly into an athlete’s routine. Players can use the portable device while traveling or relaxing, making therapy and rehabilitation more manageable.

The sam^® device from ZetrOZ Systems helps both professional athletes and everyday people return to sports and daily activities without invasive treatments or potentially addictive pain medication. For more information about ZetrOZ Systems and the sam^® wearable ultrasound device, visit www.zetroz.com or www.samrecover.com.

About ZetrOZ Systems

ZetrOZ Systems is leading the way in healing innovations in sports medicine, developing wearable bioelectronic devices to deliver sustained acoustic medicine (sam^®). Researched and funded by the federal government, ZetrOZ is built on the proprietary medical technology of 46 patents and is the exclusive manufacturer and developer of the sam^® product line, designed to treat acute and chronic musculoskeletal conditions.

Media Contact

Catherine Hoblin
choblin@zetroz.com

SOURCE: ZetrOZ Systems

View the original press release on ACCESS Newswire